Fox Run Management L.L.C. Increases Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Fox Run Management L.L.C. raised its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 69.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,435 shares of the company’s stock after purchasing an additional 8,342 shares during the quarter. Fox Run Management L.L.C.’s holdings in Amneal Pharmaceuticals were worth $162,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after buying an additional 777,568 shares in the last quarter. Barclays PLC raised its holdings in Amneal Pharmaceuticals by 134.1% during the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after acquiring an additional 169,756 shares during the period. State Street Corp boosted its holdings in shares of Amneal Pharmaceuticals by 3.8% in the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after acquiring an additional 127,753 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at $520,000. Finally, Geode Capital Management LLC raised its stake in shares of Amneal Pharmaceuticals by 11.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after purchasing an additional 378,136 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $8.28 on Friday. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48. The company has a market capitalization of $2.57 billion, a P/E ratio of -12.18 and a beta of 1.05. The firm’s 50 day simple moving average is $8.42 and its 200 day simple moving average is $8.37.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million during the quarter, compared to analysts’ expectations of $708.21 million. During the same quarter last year, the firm posted $0.14 earnings per share. On average, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 62,590 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total transaction of $501,345.90. Following the transaction, the director now directly owns 1,968,886 shares in the company, valued at $15,770,776.86. This trade represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,240,000 shares of company stock valued at $43,754,000. Corporate insiders own 26.56% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Finally, Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $10.80.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.